Cargando…

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib

The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC). However, not all HCC patients respond to sorafenib well and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Wei-Chien, Hsieh, Yi-Ling, Hung, Chao-Ming, Chien, Pei-Hsuan, Chien, Yu-Fong, Chen, Lei-Chin, Tu, Chih-Yen, Chen, Chia-Hung, Hsu, Sheng-Chieh, Lin, Yueh-Ming, Chen, Yun-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877048/ https://www.ncbi.nlm.nih.gov/pubmed/24391798 http://dx.doi.org/10.1371/journal.pone.0083627

Ejemplares similares

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
por: Chen, Yun-Ju, et al.
Publicado: (2011)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
por: Latunde-Dada, Gladys O., et al.
Publicado: (2014)

Chicken xenobiotic receptor upregulates the BCRP/ABCG2 transporter
por: Xu, Ziyong, et al.
Publicado: (2022)

In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2)
por: Ding, Yi-Lung, et al.
Publicado: (2014)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2
por: Chen, Liming, et al.
Publicado: (2019)

Effects of α-Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport
por: Takara, Kohji, et al.
Publicado: (2012)

New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
por: Westover, David, et al.
Publicado: (2015)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

Hepatitis B Virus X Upregulates HuR Protein Level to Stabilize HER2 Expression in Hepatocellular Carcinoma Cells
por: Hung, Chao-Ming, et al.
Publicado: (2014)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery
por: Cho, Wei-Ru, et al.
Publicado: (2020)

Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma
por: Lee, Wei‐Chen, et al.
Publicado: (2020)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

Association of ABCG2 rs2231142 Allele and BMI With Hyperuricemia in an East Asian Population
por: Chen, Yen-Ju, et al.
Publicado: (2021)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2
por: Hosomi, Atsushi, et al.
Publicado: (2012)

Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
por: Xie, Ni, et al.
Publicado: (2014)

Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma
por: Liao, Yi-Jen, et al.
Publicado: (2020)

The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality
por: Chiang, Chien-Hsieh, et al.
Publicado: (2016)

Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells
por: Huang, Wei-Chien, et al.
Publicado: (2016)

Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report
por: Chen, Kuo-Hsin, et al.
Publicado: (2016)

Correction: Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
Publicado: (2014)

Genistein and Glyceollin Effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells
por: Schexnayder, Chandler, et al.
Publicado: (2015)

Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging
por: Qawasmi, Israa, et al.
Publicado: (2014)

Jump into a New Fold—A Homology Based Model for the ABCG2/BCRP Multidrug Transporter
por: László, Laura, et al.
Publicado: (2016)

ABCG2/BCRP transport mechanism revealed through kinetically excited targeted molecular dynamics simulations
por: Dudas, B., et al.
Publicado: (2022)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hpks7oiribenkkg1p75rrh4bcq